Related Funds
Fund Name | Location |
ARES International | China, Jiangsu, Taiwan |
Blue Elephant Capital | Beijing, Beijing, China |
BtoBfactory Ventures | Community of Madrid, Madrid, Spain |
Chengdu Technology Transfer Group | Chengdu, China, Sichuan |
ID Global Corporation | New Zealand, Wellington, Wellington |
Keyrus | France, Ile-de-France, Levallois-perret |
Southern Africa Innovation Support | - |
Syncom Venture Partners | Maryland, Silver Spring, United States |
Wing Capital Group | Milwaukee, United States, Wisconsin |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Rippl Care | 02 Oct 2024 | Seattle, Washington, United States | |||
Tuesday Health | $60M | 21 May 2024 | Nashville, Tennessee, United States | ||
InStride Health | $30M | 27 Mar 2024 | Boston, Massachusetts, United States | ||
Nocion Therapeutics | $62M | 04 Mar 2024 | Cambridge, Massachusetts, United States | ||
Claris Biotherapeutics | $57M | 04 Jan 2024 | Jersey City, New Jersey, United States | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Abcuro | $155M | 17 Aug 2023 | Newton, Massachusetts, United States | ||
Violet Therapeutics | $10M | 05 May 2023 | Cambridge, Massachusetts, United States | ||
Mediar Therapeutics | $85M | 15 Mar 2023 | Cambridge, Massachusetts, United States |
– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Rippl Care | 02 Oct 2024 | Seattle, Washington, United States | |||
Tuesday Health | $60M | 21 May 2024 | Nashville, Tennessee, United States | ||
InStride Health | $30M | 27 Mar 2024 | Boston, Massachusetts, United States | ||
Nocion Therapeutics | $62M | 04 Mar 2024 | Cambridge, Massachusetts, United States | ||
Claris Biotherapeutics | $57M | 04 Jan 2024 | Jersey City, New Jersey, United States | ||
ROME Therapeutics | $72M | 12 Sep 2023 | Cambridge, Massachusetts, United States | ||
Abcuro | $155M | 17 Aug 2023 | Newton, Massachusetts, United States | ||
Violet Therapeutics | $10M | 05 May 2023 | Cambridge, Massachusetts, United States | ||
Mediar Therapeutics | $85M | 15 Mar 2023 | Cambridge, Massachusetts, United States |